Vapotherm's mission is to improve patient outcomes and experiences in respiratory distress by commercializing its innovative High Velocity Therapy® platform. The company has achieved global commercial adoption of its Precision Flow® systems, establishing HVNI as a standard of care in many hospitals for conditions like respiratory failure and COPD exacerbation. Its strategy focuses on expanding clinical evidence, penetrating home care markets, and leveraging its versatile platform across new indications and care settings to drive growth.
Respiratory FailureCOPDPulmonary HypertensionPost-Operative Care
Technology Platform
Proprietary High Velocity Therapy® platform that delivers heated, humidified, and oxygenated gas at high flow rates via nasal insufflation (HVNI) for non-invasive respiratory support.
Funding History
5
Total raised:$170M
IPO$75MUndisclosed
Series D$45MUndisclosed
Series C$25MUndisclosed
Series B$15MUndisclosed
Opportunities
The large and underpenetrated home respiratory care market represents a major growth frontier, driven by value-based care initiatives.
Expanding clinical evidence into new indications like pulmonary hypertension could significantly widen the addressable patient population and strengthen the value proposition.
Risk Factors
Execution risk in the competitive home care market is high, requiring successful navigation of reimbursement and sales channel challenges.
The company faces ongoing pressure from larger, well-capitalized competitors in both hospital and home settings, which could impact pricing and market share.
Competitive Landscape
Vapotherm competes with large medtech players like Fisher & Paykel, Philips, and ResMed in hospital HFNC, and with CPAP/BiPAP leaders in the home. Its differentiation lies in its proprietary humidification technology, dedicated device design, and the patient comfort of its small-bore nasal interface.
